Motilal Oswal's 7 buy calls in finance, tech and more after Q1 earnings

While overall corporate earnings surprised everyone by growing instead of falling, a handful of standout names across finance and tech, plus a few other sectors catching similar momentum, are drawing analyst attention for all the right reasons. Motilal Oswal has put fresh buy ratings or maintained their buy call on these 7 stocks after their Q1FY27 results, backed by strong growth numbers, expanding margins, and clear upside to current prices. From wealth management and insurance on the finance side to electronics manufacturing on the tech side, here's the full rundown of what's driving the optimism, and how much upside analysts see in each.

Bajaj Finserv delivered a standout quarter, with consolidated revenue jumping nearly 20% and profit rising 12% year-on-year. The real showstopper was its life insurance arm, where the value of new business surged an incredible 87%, smashing expectations. Its general insurance business also grew steadily even while waiting for the motor insurance segment to recover. With profitability improving across nearly every subsidiary, analysts just upgraded the stock straight to a Buy call, betting on continued strength across its financial ecosystem.

Rating: Upgraded to Buy | Target Price: INR 2,490 (CMP: INR 2,029, +23% upside)

Aditya Birla Capital just posted a 40% jump in profit, powered by a lending book that grew an impressive 32% year-on-year across its housing and NBFC businesses. Its insurance arms are scaling fast too — health insurance premiums shot up 50%, while its overall managed assets crossed INR7.5 trillion. The company even raised fresh growth capital from global investors to fuel further expansion. With asset quality improving and profitability on the rise, analysts see this diversified financial powerhouse as a strong long-term Buy.

Rating: Buy | Target Price: INR 480 (CMP: INR 404, +19% upside)

Nuvama Wealth's operating revenue grew 18% this quarter, comfortably beating expectations, driven by a surging capital markets business that outperformed by a wide margin. Profit came in 16% higher year-on-year, even as the company invested aggressively in new relationship managers to tap growing wealth demand beyond India's biggest cities. With a strong IPO pipeline expected to boost its investment banking arm and steady growth across wealth and asset management, analysts remain confident this wealth manager still has room to run.

Rating: Buy | Target Price: INR 2,100 (CMP: INR 1,804, +16% upside)

Dixon Technologies delivered results right in line with expectations, powered by mobile phone volumes hitting 7.5 million units for the quarter — a jump of 25% from the previous quarter alone. Recent regulatory approval for its Vivo joint venture and a fresh government manufacturing policy are opening up major new growth avenues, especially in exports. While margins came in slightly softer than hoped, analysts remain bullish on Dixon's expanding manufacturing footprint and its central role in India's electronics push, keeping their Buy rating firmly in place.

Rating: Buy | Target Price: INR 16,100 (CMP: INR 14,049, +15% upside)

GAIL delivered a massive earnings beat this quarter, with profit coming in more than double what analysts expected, thanks to a red-hot gas trading business and a key manufacturing plant returning to full production. Natural gas transmission volumes also came in ahead of estimates, prompting the company to raise its full-year guidance. While some risks remain around softer chemical prices and geopolitical uncertainty, the stock's attractive valuation and strong cash flow outlook have analysts convinced there's more upside left to capture.

Rating: Buy | Target Price: INR 206 (CMP: INR 181, +14% upside)

Global Health, which runs the Medanta hospital chain, beat expectations on both revenue and profit this quarter, powered by strong patient volumes across its network. Its Lucknow hospital has scaled from 200 to nearly 780 beds since opening, while the newer Patna facility continues rapid bed additions to meet surging demand. Even its newest Noida hospital is nearing profitability far faster than typical new hospitals usually do. With expansion running ahead of schedule, analysts have raised their estimates and kept a confident Buy rating on the stock.

Rating: Buy | Target Price: INR 1,670 (CMP: INR 1,406, +19% upside)

Sun Pharma posted profits ahead of expectations this quarter, helped by a global specialty medicine portfolio that's now growing at 13% a year and makes up nearly a quarter of total sales. While its US generics business softened due to rising competition, India's branded drug business kept up its industry-beating growth streak through aggressive brand-building. Analysts expect this international push to keep driving steady double-digit profit growth over the next two years, keeping their Buy call solidly intact.

Rating: Buy | Target Price: INR 2,310 (CMP: INR 1,991, +16% upside)

This list spans two very different worlds: finance names like Bajaj Finserv, Aditya Birla Capital and Nuvama Wealth riding strong growth in insurance and wealth management, and tech-manufacturing play Dixon Technologies capitalizing on India's electronics boom, rounded out by gas trading, hospitals and pharma. What ties all 7 together is simple: each beat Q1 expectations and earned a fresh Buy rating from Motilal Oswal, with upside estimates ranging from 14% to 23%. Which of these 7 Buy calls looks most compelling to you?